# MiRTeL Co.LTD.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mirtel-co-ltd

- Industry: Biotechnology
- Headquarters: Hiroshima, Japan
- Website: www.mirtel.co.jp
- Total disclosed funding: $7.2M
- Latest round: Series B (Jun 8, 2018)
- Investors on record: 7

## About

Established in 2012 and based in Hiroshima, Japan, MiRTeL Co.LTD. engages in the research and development of health check systems as well as the undertaking of public health tests. In August 2024, MiRTeL Co.LTD. raised JPY 60 million in venture funding from Medical Net.

The firm provides advanced health diagnostics, offering tests like the telomere test to assess disease susceptibility, the scan test for cancer risk detection, and the intestinal flora check. The company’s services focus on early detection and preventive healthcare, aiming to improve screening rates and reduce mortality from diseases like breast cancer. Moreover, the firm also collaborates with various healthcare providers and institutions for research and development.

## Funding rounds

- Series B, Jun 8, 2018, $5.3M — University of Tokyo Edge Capital Partners, Kyocera Corporation, Beyond Next Ventures, Hiroshima Venture Capital, Medical Net
- Series A, Jul 15, 2016, $1.8M — University of Tokyo Edge Capital Partners, NTT DOCOMO Ventures, MIRAIDOOR, Hiroshima Venture Capital, Medical Net

## Investors

- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Series A, Series B
- NTT DOCOMO Ventures (https://capitalatlas.ai/funds/ntt-docomo-ventures) — Series A
- MIRAIDOOR (https://capitalatlas.ai/funds/miraidoor) — Series A
- Hiroshima Venture Capital (https://capitalatlas.ai/funds/hiroshima-venture-capital) — Series A, Series B
- Medical Net — Series A, Series B
- Kyocera Corporation — Series B
- Beyond Next Ventures (https://capitalatlas.ai/funds/beyond-next-ventures) — Series B